Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Procter & Gamble Company (The) PG

Consumer Defensive — Household & Personal Products
S&P 500 Member Dividend Champion (5y)
Indexes indicate stock being part of an index ,
Growth Flags show if company had growth for consecutive years

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
67.10
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell 9 1 — 1 7 — — — — — 15 —
Insider Ownership
0.59%

Capital & Financial Ratios

Market Cap
341,550.00
Revenue
87,032.00
Net Income
16,144.00
Free Cash Flow
15,655.00
Net Debt
24,196.00
Current Ratio
0.68
Debt/Equity
0.63
P/E ratio
21.66
P/S ratio
3.93
P/B ratio
6.38
Past 5Y EPS Growth
33.28%
This Y EPS Growth
1.24%
Next Y EPS Growth
5.98%
Next 5Y EPS Growth
4.25%
in millions of $

Dividends

Payout Ratio
0.62
Annual Dividend Rate
3.76
Annual Dividend Yield
2.41%
total individual payouts
2029 ‡‡‡‡‡
2028 ‡‡‡‡‡
2027 ‡‡‡‡‡
2026 4.27
—
—
—
2025 4.18
—
—
—
—
2024 3.96
—
—
—
—
2023 3.74
—
—
—
—
2022 3.61
—
—
—
—
2021 3.40
—
—
—
—
2020 3.12
—
—
—
—
2019 2.95
—
—
—
—
2018 2.84
—
—
—
—
2017 2.74
—
—
—
—
2016 2.67
—
—
—
—
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 2026
Cash 8,246.00 9,482.00 9,556.00 9,942.00
Receivables 5,471.00 6,118.00 6,185.00 6,056.00
Inventory 7,073.00 7,016.00 7,551.00 8,170.00
Other 1,858.00 — — —
22,648.00 24,709.00 25,392.00 26,208.00
2023 2024 2025 2026
Payables 14,598.00 15,364.00 15,227.00 16,306.00
ST’ Debt 10,229.00 7,191.00 9,513.00 11,296.00
Other 9,879.00 — — —
35,756.00 33,627.00 36,058.00 38,694.00
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡
Cash Flow ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Sep Dec Mar Jun Year
’26 — — — —
—
’26 22,386.00 22,208.00 21,235.00 21,203.00
87,032.00
’25 21,737.00 21,882.00 19,776.00 20,889.00
84,284.00
’24 21,871.00 21,441.00 20,195.00 20,532.00
84,039.00
’23 20,612.00 20,773.00 20,068.00 20,553.00
82,006.00
’22 20,338.00 20,953.00 19,381.00 19,515.00
80,187.00
’21 19,318.00 19,745.00 18,109.00 18,946.00
76,118.00
in millions of $

Operating Cash Flow

Sep Dec Mar Jun Year
’26 — — — —
—
’26 5,408.00 4,972.00 4,045.00 5,131.00
19,556.00
’25 4,302.00 4,825.00 3,705.00 4,985.00
17,817.00
’24 4,904.00 5,100.00 4,088.00 5,754.00
19,846.00
’23 4,070.00 3,574.00 3,863.00 5,341.00
16,848.00
’22 4,643.00 5,121.00 3,246.00 3,713.00
16,723.00
’21 4,739.00 5,424.00 4,087.00 4,121.00
18,371.00
in millions of $

Free Cash Flow

Sep Dec Mar Jun Year
’26 — — — —
—
’26 4,216.00 3,813.00 3,511.00 4,115.00
15,655.00
’25 3,354.00 3,902.00 2,863.00 4,032.00
14,151.00
’24 3,982.00 4,288.00 3,360.00 5,240.00
16,870.00
’23 3,185.00 2,869.00 3,134.00 4,644.00
13,832.00
’22 3,637.00 4,507.00 2,501.00 3,032.00
13,677.00
’21 3,910.00 4,875.00 3,432.00 3,409.00
15,626.00
in millions of $

EPS

Sep Dec Mar Jun Year
’26 — — — —
—
’26 1.95 1.78 1.63 1.26
6.62
’25 1.61 1.88 1.54 1.48
6.51
’24 1.83 1.40 1.52 1.27
6.02
’23 1.57 1.59 1.37 1.37
5.90
’22 1.61 1.66 1.33 1.21
5.81
’21 1.63 1.47 1.26 1.13
5.50

Target Price Range

High
‡‡‡‡‡
‡‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡‡

Recommendation Rating

2.2
1
Buy
2
3
Hold
4
5
Sell
2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 122.18 135.83 146.28 138.14 137.62 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 165.35 158.38 180.43 179.99 167.25 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 106,000 107,000 108,000 109,000 104,000 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.76 0.77 0.78 0.77 0.84 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 80,187.00 82,006.00 84,039.00 84,284.00 87,032.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 47.43% 47.86% 51.39% 51.16% 50.18% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 17,995.00 18,353.00 18,761.00 20,167.00 20,377.00 — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 22.44% 22.38% 22.32% 23.93% 23.41% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 14,793.00 14,738.00 14,974.00 16,065.00 16,144.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2,807.00 2,714.00 2,896.00 2,847.00 3,160.00 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 33.27 34.63 35.61 35.86 37.29 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 6.00 6.07 6.18 6.67 6.75 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.94 7.11 8.41 7.58 8.38 — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.26) (1.27) (1.26) (1.56) (1.67) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.67 5.84 7.15 6.02 6.71 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 19.44 19.87 21.42 22.25 23.27 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2,410.30 2,368.20 2,360.10 2,350.10 2,333.70 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 24.17 25.16 26.29 23.85 21.69 ‡‡‡‡ ‡‡‡‡ —
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.32 4.38 4.57 4.44 3.93 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7.53 7.77 7.72 7.27 6.39 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.62 4.70 4.84 4.74 4.21 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 27.12 27.89 24.13 28.22 23.41 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 16,723.00 16,848.00 19,846.00 17,817.00 19,556.00 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (3,046.00) (3,016.00) (2,976.00) (3,666.00) (3,901.00) ‡‡‡‡‡ — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 13,677.00 13,832.00 16,870.00 14,151.00 15,655.00 — — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (11,428.00) (13,108.00) (8,918.00) (10,666.00) (12,486.00) — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 31,493.00 34,607.00 32,460.00 34,508.00 34,138.00 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 24,279.00 26,361.00 22,978.00 24,952.00 24,196.00 — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 46,854.00 47,065.00 50,559.00 52,284.00 54,311.00 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 12.23% 12.07% 12.00% 12.67% 12.52% — — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 15.65% 15.44% 15.76% 16.55% 15.72% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 31.51% 31.15% 30.40% 30.97% 29.99% — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Procter & Gamble (PG) exemplifies the steady strength of consumer staples, with revenue climbing from $65.3 billion in 2016 to $84 billion in 2024 at a 3.2% CAGR, accelerating post-pandemic and projected to hit $92.1 billion by 2028. Efficiency shines through rising revenue per employee (up 25%) and gross margins rebounding to 51.4%, while EPS has grown 63% to $6.18, backed by robust free cash flow, high ROE over 30%, and aggressive buybacks shrinking shares by 13%. A rock-solid balance sheet with stable debt and negative working capital underscores its defensive edge, delivering 110% stock gains since 2016 amid inflation, trade wars, and recessions.

Yet, red flags merit attention: heavy insider selling totaling $43 million in 2025-2026 with zero buys, including from the CEO, contrasts bullish projections and premium valuations (26x PE vs. 23.5x average). Analyst targets suggest modest 6% upside on average, tempering enthusiasm amid post-COVID demand normalization and risks like geopolitical disruptions.

PG’s 68-year dividend streak and health/beauty growth potential position it as a generational hold like Coke in stagflation eras, but stretched multiples call for a tactical overweight—dive into the full analysis for Q1 2026 earnings insights and buy/hold timing.

Read full commentary →

Procter & Gamble Company (The) (PG) Latest News

News by impact score

Fine-tune

18 Sep

3 , 11:32 AM
High gas prices may raise transportation and production costs for Procter & Gamble, creating risk of reduced earnings and margin pressure in upcoming quarters. Elevated fuel expenses can lift logistics and input costs enough to affect near-term margins but remain manageable through pricing actions.

14 Sep

3 , 11:07 AM
Procter & Gamble's Fabric & Home Care segment faces challenges in regaining momentum amid competitive pressures and shifting consumer demand. Segment performance issues may moderately affect PG financial results and positioning without fundamentally shifting company trajectory.

10 Sep

4 www.marketbeat.com, 10:05 AM
Procter & Gamble is overhauling its supply chain and deploying AI to drive a growth rebound. AI deployment and supply chain overhaul constitute major strategic initiatives that can materially improve efficiency and growth trajectory.

7 Sep

3 , 12:58 PM
Procter & Gamble faces margin pressures that signal potential challenges to profitability and prompt caution on near-term stock performance. Margin pressures affect PG profitability and may shift investor sentiment without fundamentally changing company trajectory.

2 Sep

3 , 10:06 AM
Procter & Gamble Fabric & Home Care shows mixed trends, leaving uncertainty over whether growth lies ahead for the segment. Mixed trends in a major PG segment point to moderate effects on financial results and positioning.

1 Sep

3 247wallst.com, 9:05 AM
Procter & Gamble's steady dividend growth delivers stronger investor returns and stability than Johnson & Johnson's growth-focused strategy. PG's dividend edge may lift investor sentiment and valuation multiples without altering core operations.

31 Aug

4 , 11:23 AM
P&G fiscal 2027 outlook introduces an 8% core EPS headwind. An 8% core EPS headwind in the fiscal 2027 outlook signals substantial pressure on P&G earnings trajectory and investor views.

21 Aug

3 , 7:11 PM
P&G advances product innovations in Charmin and Swiffer to strengthen its brand moat and competitive positioning in consumer goods. Ongoing innovations in core household brands support incremental gains in P&G's competitive positioning and market perception.

11 Aug

3 , 11:14 AM
Procter & Gamble issued 2027 financial guidance, raising questions on whether current stock valuation appears elevated. Long-term guidance shapes investor views on future performance but stops short of immediate operational shifts.

10 Aug

4 www.thestreet.com, 1:34 PM
Procter & Gamble unlocked an unexpected new growth engine that could expand revenue streams beyond its long-standing dividend focus. New growth engine discovery signals major strategic expansion likely to lift long-term revenue and investor outlook.

9 Aug

4 , 2:35 PM
P&G's $3.8B wellness acquisition collides with a costly outlook that pressures the company's financial trajectory and market performance. P&G's $3.8B wellness deal introduces major cost pressures that can significantly alter the company's financial trajectory and investor sentiment.

3 , 2:12 AM
Jon Moeller's retirement at Procter & Gamble raises questions about the implications of a potential chairman change for the company's future direction. Chairman transition after CEO retirement may affect strategic continuity and investor sentiment at Procter & Gamble.

7 Aug

4 transcript www.fool.com, 7:58 PM
Procter & Gamble released its Q4 2026 earnings call transcript covering financial results, segment performance, and management outlook. Earnings figures and guidance directly move investor sentiment and near-term stock valuation.

6 Aug

3 www.theflowspace.com, 2:32 PM
Procter & Gamble acquires supplement brand Thorne, drawing public reactions. Thorne purchase adds nutritional supplements to P&G lineup and may modestly shift wellness positioning.

5 Aug

3 www.barchart.com, 11:14 AM
Procter & Gamble stock draws attention over a $3.8 billion development likely tied to operations or legal matters. A $3.8 billion item points to noticeable but not transformative effects on financials and investor view.

4 Aug

4 , 6:10 PM
Procter & Gamble agrees to acquire Thorne for $3.8 billion. The $3.8 billion acquisition of Thorne marks a major strategic expansion into the health and wellness sector.

4 www.cincinnati.com, 3:54 PM
P&G acquires Thorne for $3.8B in a deal larger than its prior acquisitions, expanding into personalized health and nutrition markets. $3.8B Thorne purchase marks major strategic expansion that could significantly alter P&G portfolio trajectory and investor outlook.

4 wwd.com, 2:04 PM
Procter & Gamble agrees to acquire Thorne for $3.8 billion to expand its personal health care portfolio. The $3.8 billion Thorne acquisition marks a major strategic expansion into personal health care.

4 www.cincinnati.com, 1:50 PM
Procter & Gamble acquires supplements maker Thorne for $3.8 billion. The $3.8 billion acquisition of Thorne marks a major strategic expansion into the supplements sector.

4 , 1:45 PM
L Catterton sells Thorne to Procter & Gamble for $3.8 billion. The $3.8 billion acquisition of Thorne adds a major health supplements business to Procter & Gamble's portfolio.

4 qz.com, 1:31 PM
Procter & Gamble acquires supplement brand Thorne for $3.8 billion. The $3.8 billion acquisition of Thorne marks a major strategic expansion into health supplements.

4 , 1:15 PM
Procter & Gamble is acquiring Thorne for $3.8 billion, CEO says. $3.8 billion Thorne acquisition marks major strategic expansion for Procter & Gamble.

4 stocktwits.com, 1:07 PM
Procter & Gamble plans to acquire Thorne in a $3.8 billion deal, with CEO Jejurikar stating the firm is really happy with the asset. The $3.8 billion Thorne acquisition constitutes a major strategic expansion that can significantly shift Procter & Gamble's trajectory.

3 , 1:00 PM
Procter & Gamble enters definitive agreement to acquire Thorne. Deal adds Thorne's supplements portfolio to Procter & Gamble's consumer health lineup.

3 , 1:17 AM
Procter & Gamble reports Q2 margin pressure while market share remains stable, shaping a cautious future outlook. Margin pressure directly affects profitability and may influence investor views on near-term results despite stable share.

3 Aug

3 www.fool.com, 5:29 AM
Procter & Gamble guided below estimates and its stock sits 5% above a 52-week low. The author withholds a buy decision until unspecified conditions are met. Below-estimate guidance signals potential shortfalls that could pressure near-term earnings and investor sentiment without fundamentally altering long-term trajectory.

30 Jul

4 transcript www.marketbeat.com, 3:03 AM
Procter & Gamble released Q4 earnings call highlights covering financial results, guidance and operational updates. Q4 earnings and guidance directly shape investor expectations for revenue, margins and strategic direction.

3 , 3:51 PM
Procter & Gamble shares decline 1.8% on looming one billion dollar cost hit. One billion dollar cost hit pressures near-term earnings without fundamentally altering long-term trajectory.

3 , 10:00 AM
PG's Q4 earnings call highlighted a reset in consumer growth strategies amid shifting market dynamics. Q4 earnings call details on consumer growth reset point to moderate effects on PG financial outlook and investor sentiment.

29 Jul

3 transcript app.moby.co, 5:10 PM
Procter & Gamble Company released its Q4 2026 earnings call summary covering financial results, operational updates and forward guidance. Quarterly earnings updates deliver financial metrics and outlook that moderately influence near-term stock movement and sentiment.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us